Live·Open questions in longevity research
All news
TherapeuticsLongevity research

Researcher Jonathan Ouyang proposes selectively inhibiting protein synthesis in cancer and improving its quality control when it falters with age

16 November 2026· 261116002

Researcher Jonathan Ouyang proposes selectively inhibiting protein synthesis in cancer and improving its quality control when it falters with age

On November 13, Jonathan Ouyang, founder of the biotechnology company Collide Therapeutics, published a drug development agenda. The proposed drugs would target ribosomes, the cellular machinery that builds proteins using RNA instructions.

Many antibiotics block bacterial ribosomes. Differences between bacterial and human ribosomes allow these drugs to act primarily on bacteria. A drug that inhibits protein synthesis in human cells disrupts healthy tissue function. This is how omacetaxine, which the FDA approved in 2012, works in treating chronic myeloid leukemia, a type of blood cancer. It harms normal blood-forming cells as well as malignant cells. The goal for the next generation of drugs is to selectively inhibit the production of proteins that sustain tumor growth.

The molecule PF846 demonstrated that protein synthesis can be stalled selectively. In a 2017 study, it stalled ribosomes as they synthesized certain proteins. In a control experiment, researchers rewrote the RNA instructions while preserving the encoded protein sequence, and the molecule remained active. When they changed the protein sequence while leaving the RNA nearly unchanged, PF846 stopped inhibiting protein synthesis. Its selectivity therefore depended on the growing protein.

In a 2026 study by Interdict Bio, researchers targeted the region of the ribosome where the next amino acid is added to the chain. The chain is extended at this site, which they reasoned could help them identify molecules that bind to specific amino acids. By changing the molecules' chemical groups, they induced stalling at different combinations of amino acids. Experiments with designed protein sequences confirmed this dependence, and electron microscopy showed that a molecule contacted both the ribosome and the unfinished protein. A protein can be targeted while it is still being synthesized, before it adopts its final shape.

Ribosomes also stall as part of age-related dysfunction. In 2022 experiments in yeast and roundworms, ribosomes stalled more often at specific points along the RNA instructions as the organisms aged; ribosomes following behind collided with them. A quality control system releases stalled ribosomes and removes unfinished chains. In old yeast, this system became overloaded: fragments accumulated and clumped together. Ouyang therefore proposes searching for drugs that restore this system, which is also the focus of his company, Collide Therapeutics.

Cells can respond to stress by slowing protein synthesis; DNL343 was developed to relieve this inhibition. In a 24-week trial whose results were announced in January 2025, it did not show a slowing of amyotrophic lateral sclerosis compared with placebo. This disease destroys the nerve cells that control muscles. Ouyang interprets failures of this kind as “an excellent mechanism tested in the wrong disease.” He proposes matching each drug to a specific defect: inhibiting the synthesis of particular proteins, relieving inhibition of protein synthesis, or restoring the quality control system.

Separately, Ouyang predicts that an anti-aging therapy that reduces errors during protein synthesis will have completed phase one human trials by October 2032. This phase primarily assesses safety.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#ribosomes#protein-synthesis#cancer#ribosome-quality-control#aging#collide-therapeutics